Scarica l'app Stockscreener
11.21
6.39%
-0.765
Dopo l'orario di chiusura:
11.40
0.185
+1.65%
Precedente Chiudi:
$11.98
Aprire:
$11.8
Volume 24 ore:
1.72M
Relative Volume:
1.98
Capitalizzazione di mercato:
$1.45B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-12.59%
1M Prestazione:
-36.82%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.10
$12.32
Intervallo di 1 settimana:
$11.10
$13.22
Portata 52W:
$11.10
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Nome
Kailera Therapeutics Inc
Settore
Industria
Telefono
508-440-9475
Indirizzo
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
11.21 | 1.45B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-12 | Iniziato | Evercore ISI | Outperform |
| 2026-05-12 | Iniziato | JP Morgan | Overweight |
| 2026-05-12 | Iniziato | Jefferies | Buy |
| 2026-05-12 | Iniziato | Leerink Partners | Outperform |
| 2026-05-12 | Iniziato | TD Cowen | Buy |
| 2026-05-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Kailera Therapeutics Inc Borsa (KLRA) Ultime notizie
868,160 Shares of Kailera Therapeutics, Inc. $KLRA Acquired by State Street Corp - MarketBeat
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
KLRA: Differentiated GLP-1 assets and strategy position the company for growth in the expanding obesity market - TradingView
Kailera at bernstein healthcare forum: betting on obesity differentiation By Investing.com - Investing.com Canada
Kailera at bernstein healthcare forum: betting on obesity differentiation - Investing.com
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month LowWhat's Next? - MarketBeat
Weight-loss drug developers line up to tap lucrative market as competition heats up - Reuters
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 5.5%Time to Sell? - MarketBeat
Kailera Therapeutics, Inc.(NasdaqGS:KLRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P Global BMI Index - marketscreener.com
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation (KLRA) - Seeking Alpha
Kailera Therapeutics targets obesity with GLP-1 drug, raising $718M in IPO despite 40% share drop. - Pluang
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval - Seeking Alpha
Kailera Therapeutics to Participate in September Investor Conferences - The Manila Times
Kailera Therapeutics to Participate in Upcoming Investor Conferences - Quiver Quantitative
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowTime to Sell? - MarketBeat
Four executives will appear in Kailera's September webcasts - Stock Titan
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth” - finance.yahoo.com
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week LowWhat's Next? - MarketBeat
Kailera Therapeutics (KLRA) grants CTO 220,000 stock options - Stock Titan
Kailera Therapeutics (KLRA) CTO reports no shares in first ownership filing - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7%Should You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - MarketBeat
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - MarketBeat
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Stock Falls 12.5%, Leaving Market Value Just $930 Million Above Cash - ts2.tech
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - MarketBeat
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Therapeutics Inc Azioni (KLRA) Dati Finanziari
Non sono disponibili dati finanziari per Kailera Therapeutics Inc (KLRA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):